1. Introduction {#sec1}
===============

Uncoupling protein 2 (UCP2) is a member of the mitochondrial anion carrier superfamily that, when activated, can partially uncouple aerobic respiration from ATP synthesis [@bib1], [@bib2], [@bib3]. *Ucp2* is expressed in many tissues, including the pancreatic β cell [@bib4], which relies heavily on glucose metabolism coupled to ATP production for efficient and appropriate insulin secretion. Not surprisingly, numerous gain-of-function [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10] and loss-of-function [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16] studies have been used to interrogate the function of UCP2 in the β cell and, for the most part, have established a negative relationship between UCP2 and glucose-stimulated insulin secretion (GSIS). For example, whole body (*Ucp2*^*-/-*^) [@bib11], [@bib12] and β cell *Ucp2* knockout (*Ucp2-*βKO) mice [@bib14] show augmented GSIS, whereas overexpression of *Ucp2* in clonal β cell cultures and rat islets impairs GSIS [@bib5], [@bib9]. Furthermore, *Ucp2* mRNA and protein are markedly upregulated in isolated islets from animal models of type 2 diabetes (T2D) and obesity [@bib11], [@bib12], [@bib17], [@bib18], and treatment of isolated islets *in vitro* with high glucose and elevated lipid concentrations significantly increases *Ucp2* expression [@bib13], [@bib19], [@bib20]. There is also sufficient evidence that suppression of insulin secretion in humans at risk for T2D is associated with higher expression levels of *Ucp2* [@bib21], [@bib22], [@bib23].

The negative relationship between *Ucp2* expression and GSIS has been dubbed a "surprising whim of nature" [@bib24], [@bib25] and has provoked us and other research groups to ask an important evolutionary question: Why do β cells express *Ucp2* if its activity is detrimental to insulin secretion and metabolic health? It is thought that *Ucp2* must have an important physiological role in the β cell or it would have been selected against during evolution. Notably, obesity and over-nutrition are relatively 'modern' phenomena; humans evolved in an environment that was prone to prolonged periods of fasting and, in some cases, starvation [@bib26]. The metabolic response to fasting is tightly regulated by insulin such that suppression of insulin during fasting is essential to allow for efficient endogenous glucose production and lipolysis to release metabolic fuels when dietary glucose is not sufficiently available. As such, it has been suggested that the true physiological function of *Ucp2*/UCP2 is to coordinate insulin secretion capacity with fluctuating nutrient supply, such that upregulation of *Ucp2*/UCP2 during fasting inhibits insulin secretion to promote fuel mobilization and prevent hypoglycemia [@bib25], [@bib27], [@bib28]. Interestingly, *Ucp2* mRNA is upregulated in islets and whole pancreas of starved mice [@bib29], and rats [@bib30] and fasted *Ucp2*^*-/-*^ mice display higher serum insulin levels and blunted lipid metabolic responses [@bib25]. Only a few studies have examined the role of UCP2 in the β cell during fasting, and all have employed either long-term (i.e. \>24 h) or supra-physiological fasts (i.e. artificially fasting the animals overnight during the normal wake/fed period); however, our diurnal nature dictates that we cycle between acute periods of fasting and feeding on a daily basis, and therefore, UCP2 may play an important physiological role in coordinating insulin secretion with the acute phases of fasting and feeding experienced on a daily basis. The temporal expression of *Ucp2* and its contribution to GSIS capacity over the course of a daily cycle in a healthy β cell has not yet been assessed.

In this study, we hypothesized that *Ucp2* mRNA is dynamically expressed in healthy β cells over the course of a 24 h daily cycle such that *Ucp2* expression is low in the fed/active phase to promote maximal GSIS capacity and upregulation of *Ucp2* in the fasted/inactive phase suppresses GSIS capacity. To test this, we used synchronized MIN6 clonal β cells and islets isolated from wild type (WT) and *Ucp2-*βKO mouse models to define the daily expression patterns of *Ucp2* mRNA, temporal GSIS capacity and glucose tolerance over 24 h. We have further explored the mechanistic contribution of UCP2 to the control of GSIS by examining changes in glucose-induced ATP production over the course of the 24 h cycle. Here, we demonstrate that *Ucp2*/UCP2 plays an important role in the regulation of temporal GSIS capacity, which is vital for the maintenance of glucose tolerance in the inactive/fasted phase of the daily cycle.

2. Materials & methods {#sec2}
======================

2.1. Animals {#sec2.1}
------------

*Ucp2-*βKO mice were generated and characterized previously [@bib14]. *Ins2*-cre and *Ucp2-*βKO mice were maintained in closed colonies and were age-matched (12--24 weeks old) for experimentation. Note that based on similar results obtained between these mice (*Ins2*-cre and *Ucp2-*βKO) and other models of experimentation (MIN6 cells and C57BL6 mice), we have no reason to suspect that genetic background or genomic variation in these colonies is a confounding issue in this study. C57BL6 mice were obtained from breeding colonies housed at the University of Manitoba Central Animal Care Facility. Only male mice were used for experimentation. All animal experiments were approved by the University of Manitoba Animal Care Committee, and animals were handled according to the guidelines of the Canadian Council of Animal Care.

2.2. MIN6 cells and synchronization {#sec2.2}
-----------------------------------

MIN6 cells were cultured in DMEM (4500 mg/l glucose and [l]{.smallcaps}-glutamine) (Gibco, Thermo Fisher, Waltham, MA, USA) supplemented with 10% fetal bovine serum (Thermo Fisher, Waltham, MA, USA) and 1% penicillin/streptomycin (VWR, Radnor, PA, USA). MIN6 cells were plated in 6-well tissue culture dishes for approximately 2 days, until they were 60--70% confluent. MIN6 cells were synchronized prior to experimentation using a previously described serum-starve/serum-shock protocol [@bib31]. For genipin-treated cells, 50 μM genipin (Wako Chemicals, Richmond, VA, USA) (dissolved in 70% ethanol) was applied 1 h prior to the start of the experiment and maintained throughout. Control cells in these experiments were treated with the same volume of 70% ethanol only.

2.3. Islet isolations {#sec2.3}
---------------------

Islets were isolated by collagenase IV (Sigma, Oakville, ON, CA) digestion of the pancreas, according to our previously established protocol [@bib14]. Once digested, islets were hand-picked 3--4 times into fresh RPMI 1640 media (11.1 mM glucose; Gibco, Thermo Fisher, Waltham, MA, USA), supplemented with 10% FBS (Thermo Fisher, Waltham, MA, USA), 1% PenStrep (VWR, Radnor, PA, USA) and 1% [l]{.smallcaps}-Gluatmine (Hyclone. GE Healthcare, Logan, Utah, USA). Picked islets were allowed to rest for 1 h at 37 °C/5% CO~2~ and then immediately used for experimentation. For genipin treatment of isolated islets, 50 μM genipin (Wako Chemicals, Richmond, VA, USA) (dissolved in 70% ethanol) was applied 1 h prior to the start of the experiment and maintained throughout.

2.4. Quantitative real-time PCR (qPCR) {#sec2.4}
--------------------------------------

RNA was isolated from MIN6 cells and islets (∼200 islets) using the RNeasy Plus Mini Kit (Qiagen, Germantown, MD, USA) or the RNeasy Micro Plus Kit (Qiagen, Germantown, MD, USA), respectively. RNA was reverse transcribed into cDNA using the Quantitect Reverse Transcription kit (Qiagen, Germantown, MD, USA) according to the manufacturer\'s instructions. 50--100 ng of cDNA was used as the template for qPCR reaction using the Quantitect SYBR green PCR kit (Qiagen, Germantown, MD, USA) in a MicroAmp Optical 96-well reaction plate with barcode (Applied Biosciences). qPCR reactions were run on an ABI 7500 real time system (Applied Biosystems, Thermo Fisher, Waltham, MA, USA) using the following program: 95 °C for 15 min, followed by 40 cycles of: 95 °C for 15 s, 57 °C for 30 s, and 72 °C for 30 s. Data was normalized to *Eif*2α mRNA and expressed relative to the expression level at time zero of the experiment, or otherwise indicated, to determine the 2^−ΔΔCT^. *Ucp2* primers: (F) GAGATGTAGGGAAACTCCAGAAC and (R) GCCTTGTCTTCTGTAGGTCTATG; *Eif*2α primers: (F) CCTGAAGTGTGATCCTGTGTTT and (R) CCAAATCCAGCCAGCACTAATA (Invitrogen, Thermo Fisher, Waltham, MA, USA).

2.5. Glucose tolerance tests (GTT) and blood glucose measurements {#sec2.5}
-----------------------------------------------------------------

Prior to beginning the GTT, mice were fasted for 3 h to ensure baseline blood glucose levels immediately prior to the time of day that the GTT was performed. i.p. glucose was administered at 1 g/kg and blood glucose was measured using a glucometer at the tail vein at 10, 20, 30, 60 and 120 min after i.p. injection.

2.6. Glucose-stimulated insulin secretion assay {#sec2.6}
-----------------------------------------------

GSIS assays were performed as described previously [@bib14]. Insulin concentration was measured using a mouse insulin ELISA kit (ALPCO, Salem, NH, USA).

2.7. ATP content measurements {#sec2.7}
-----------------------------

MIN6 cells or 10--15 islets were incubated in either 2.8 mM glucose or stimulated with 16.7 mM glucose (as described in [@bib14]). The media was removed and the cells/islets were washed two times with sterile PBS. Cells were lysed with 300 μl or 100 μl, respectively, of 0.1 M NaOH/0.5 mM EDTA buffer for 20 min at 60 °C and stored at −80 °C until assayed. The ATP Bioluminescent Assay Kit (Sigma, Oakville, ON, CA) was adapted to a 96-well plate format and the assay performed according to the manufacturer\'s instructions. Luminescence was detected and quantified using a Fluostar Optima microplate reader (BMG Labtech, Ortenberg, Germany). ATP concentrations were normalized to total μg of DNA.

2.8. Statistics {#sec2.8}
---------------

Statistical significance was assessed by two-tailed Student t-test or one- or two-way ANOVA for repeated measures, followed by a Bonferroni post-test comparisons using Prism 6 software (GraphPad, San Diego, CA, USA). A value of P \< 0.05 was considered significant. All data are expressed as the mean +/− SEM.

3. Results {#sec3}
==========

3.1. *Ucp2* mRNA expression is dynamic over 24 h and regulates inverse patterns of GSIS capacity in both MIN6 cells and isolated islets {#sec3.1}
---------------------------------------------------------------------------------------------------------------------------------------

We first set out to determine the dynamics of *Ucp2* mRNA expression over a 24 h period using MIN6 cells. To accomplish this, MIN6 cells were synchronized using an established serum-starve/serum-shock protocol [@bib31] and lysates collected every 4 h over 36 h for gene expression analyses by qPCR. *Ucp2* mRNA transcript levels displayed a dynamic and rhythmic pattern showing approximate 12 h repeating and alternating patterns of low and elevated *Ucp2* mRNA expression ([Figure 1](#fig1){ref-type="fig"}A). At Zeitgeber time (ZT) 0, 4, and 8 (note: Zeitgeber time refers to time post-entrainment; in this case, after serum shock), *Ucp2* mRNA expression remained low and unchanged. At ZT 12 and 16, *Ucp2* mRNA levels increased 1.85 (+/− 0.254; p = 0.0102) and 2.318 (+/− 0.533; p = 0.0259) --fold, respectively, compared to time 0. Between ZT 24 and ZT 28, *Ucp2* mRNA expression levels returned to baseline and gradually increased over the next 12 h (up to 36 h). Notably, beyond ZT 24, a trend towards a subsequent increase in *Ucp2* mRNA was observed up to ZT 36, although not statistically significant by 36 h, likely due to waning synchronicity of the MIN6 cultures.Figure 1Dynamic expression pattern of *Ucp2* regulates the temporal capacity of GSIS in MIN6 cells. **(A)***Ucp2* mRNA expression levels at 4 h intervals over 36 h in synchronized MIN6 cells. *Ucp2* mRNA shown is expressed relative to *Eif*2α levels and normalized to mRNA levels at time 0 (immediately after synchronization). N = 4--6 independent experiments. **(B) i.** GSIS capacity of synchronized MIN6 cells every 4 h over 36 h as measured by static incubation assay. Open circles represent insulin secreted when MIN6 cells are exposed to low (2.8 mM) glucose. Closed circles represent insulin secretion when MIN6 cells are exposed to high glucose (16.7 mM). N = 7--8 independent experiments. **ii.** Average GSIS capacity over segmented 12 h periods. GSIS is presented as the fold-change in insulin secretion above basal (2.8 mM glucose) when stimulated with high (16.7 mM) glucose. **(C)** GSIS capacity at 4 and 16 h post-synchronization in MIN6 cells treated with (hatched bars) and without genipin (solid black bars), a UCP2 activity inhibitor. Genipin was applied at a final concentration of 50 μM, 1 h before start of GSIS assay and remained present throughout the assay. N = 5. \*p \< 0.01; \*\*p \< 0.01; \*\*\*\*p \< 0.0001.Figure 1

Next, the temporal capacity of GSIS over 24 h in synchronized MIN6 cells was established by performing static incubation assays in low (2.8 mM) and high (16.7 mM) glucose concentrations every 4 h over a 36-hour time course. GSIS capacity varied in a repeatable pattern over 36 h ([Figure 1](#fig1){ref-type="fig"}B): From ZT 0 to ZT 12, stimulation with high glucose triggered an average 4.12-fold increase in insulin secretion; whereas during the next 12 h period (from ZT 16 to ZT 24), GSIS was significantly suppressed, showing only a 2-fold increase when stimulated with high glucose. Beyond 24 h (ZT 28 to ZT 36), GSIS capacity was again significantly increased, showing an average 3.47-fold increase when stimulated with high glucose. For the most part, the observed rhythmic pattern of GSIS capacity ([Figure 1](#fig1){ref-type="fig"}B) was opposite to the expression level of *Ucp2* mRNA ([Figure 1](#fig1){ref-type="fig"}A), with the exception of the 12 h time point. At this time, *Ucp2* mRNA increased almost 2-fold, but suppression of GSIS was not yet observed (suppression observed at 16 h). This lag in suppression of GSIS likely represents a lag in the translation of *Ucp2* mRNA into functional protein. Unfortunately, protein levels were not measured due the lack of an available antibody that has sufficient sensitivity and specificity for UCP2. To demonstrate that rhythmic GSIS was dependent on rhythmic UCP2 activity, we performed GSIS assays at ZT 4 and ZT 16 (time points that correspond to robust and suppressed GSIS, respectively) in the presence of genipin, a well-established pharmacological UCP2 inhibitor [@bib32], [@bib33], [@bib34]. Application of genipin prevented the suppression of GSIS in control MIN6 cells at ZT 16 but had no effect on GSIS capacity at ZT 4 when *Ucp2* mRNA expression was low ([Figure 1](#fig1){ref-type="fig"}C), suggesting that UCP2 activity at ZT 16 contributes to the suppression of GSIS at this time point. Together, these data demonstrate that rhythmic GSIS capacity is dependent on inverse rhythms of *Ucp2* expression/UCP2 activity in MIN6 cells.

To determine if rhythmic GSIS capacity is dependent on rhythmic *Ucp2* expression in primary β cells, we exploited our previously generated and characterized β cell *Ucp2* knockout mice (*Ins2Cre:Ucp2*^*fl/fl*^; commonly referred to as *Ucp2-*βKO) [@bib14]. Similar to MIN6 cells, control (*Ins2Cre:Ucp2*^*+/+*^; commonly referred to as *Ins2*-cre) islets isolated at 4 h intervals over 24 h (lights on at 6am = ZT 0; lights off at 6pm = ZT12) displayed a rhythmic capacity for GSIS that was suppressed in the light/inactive phase of the daily cycle (ZT 0, 4, 8), but became more robust in the dark/active phase (ZT 12, 16, 20) ([Figure 2](#fig2){ref-type="fig"}A,C). Suppression of GSIS in isolated *Ins2*-cre islets at ZT 4 was associated with elevated islet *Ucp2* mRNA expression, whereas the more robust GSIS observed at ZT 16 was associated with reduced islet *Ucp2* mRNA ([Figure 2](#fig2){ref-type="fig"}E). Importantly, daily rhythms of GSIS were lost in islets isolated from *Ucp2-*βKO mice, which displayed robust GSIS across the full 24 h time course ([Figure 2](#fig2){ref-type="fig"}B,D). No differences in fasted plasma insulin levels or fasted blood glucose levels were observed over 24 h between the *Ins2*-cre control and the *Ucp2-*βKO mice (data not shown).Figure 2Daily rhythms of GSIS capacity are dependent on *Ucp2*/UCP2 in isolated islets. **(A)** GSIS capacity assessed every 4 h over 24 h in *Ins2*-cre (control) isolated islets. Data for insulin secretion capacities at 2.8 mM glucose (open circles) and 16.7 mM glucose (black circles) are shown for each time point. N = 4--5 mice per time point. **(B)** GSIS capacity assessed at 4 h intervals over 24 h in islets isolated from *Ucp2-*βKO mice. Data for insulin secretion capacities at 2.8 mM glucose (open circles) and 16.7 mM glucose (black circles) are shown for each time point. N = 4--13 mice per time point. **(C)** Left panel: GSIS capacity presented as the fold-change in insulin secretion above basal (2.8 mM glucose) when stimulated with high (16.7 mM) glucose at each time point in islets isolated from *Ins2*-cre mice. Right panel: Average GSIS capacity of isolated islets from *Ins2*-cre mice in the light vs. dark periods. **(D)** Left panel: GSIS capacity presented as the fold-change in insulin secretion above basal (2.8 mM glucose) when stimulated with high (16.7 mM) glucose at each time point in islets isolated from *Ucp2-*βKO mice. Right panel: Average GSIS capacity of isolated islets from *Ucp2-*βKO mice in the light vs. dark periods. **(E)** Islet *Ucp2* mRNA levels are significantly elevated at ZT 4 (light/inactive phase) compared to ZT 16 (dark/active phase) in *Ins2*-cre control mice. *Ucp2* mRNA shown is expressed relative to *Eif2*α levels and normalized to *Ucp2* mRNA levels ZT 16. Islets were isolated from 3 to 5 mice at each time point. \*p \< 0.05. **(F)** Insulin secretion capacity measured in islets isolated from WT (C57BL6) mice at ZT4 (10 am) and ZT16 (10 pm). Application of genipin (50 μM, 1 h before assay) shows that inhibition of UCP2 at ZT4 prevents suppression of GSIS at this time point. N = 5--9 mice per time point. \*p \< 0.05; \*\*p \< 0.01; \*\*\*\*p \< 0.0001.Figure 2

To reduce genotype and strain effects, we also isolated islets from wild type (WT) C57BL6 mice and treated them with and without genipin to manipulate UCP2 activity prior to performing insulin secretion assays. Similar to *Ins2*-cre islets, C57BL6 islets displayed suppressed GSIS at ZT 4 in the light/inactive phase and robust GSIS capacity at ZT 16 in the dark/active phase ([Figure 2](#fig2){ref-type="fig"}F, black bars). Pre-treatment of isolated C57BL6 islets with genipin reversed the suppression of GSIS observed at the ZT 4 time point ([Figure 2](#fig2){ref-type="fig"}F, striped bars). Together, these data suggest that UCP2 plays an important physiological role in controlling the temporal capacity of GSIS such that increased *Ucp2* expression/UCP2 activity are required for the normal suppression of GSIS in the light/inactive phase of the daily cycle.

3.2. Daily rhythms of UCP2 activity contribute to the temporal control of glucose-induced ATP production in both MIN6 cells and isolated islets {#sec3.2}
-----------------------------------------------------------------------------------------------------------------------------------------------

Currently, the contribution of β cell UCP2 to the regulation of mitochondrial ATP production remains debatable, with some groups demonstrating that manipulation of *Ucp2* levels impact β cell ATP content [@bib6], [@bib11], [@bib12], [@bib35] while others show no impact on ATP [@bib14], [@bib36]; however, all studies performed to date have only examined ATP at a single time point and dynamic *Ucp2* expression may contribute to these debateable findings. To determine if rhythmic UCP2 contributes to the control of cellular ATP levels in a temporal manner, we examined glucose-stimulated ATP content in both synchronized MIN6 cells and islets isolated at key time points (ZT 4 and ZT 16) plus or minus genipin treatment. In synchronized MIN6 cells at ZT 4 (a time point when MIN6 cells have a high GSIS capacity), 16.7 mM glucose significantly increased cellular ATP content; however, at ZT 16 (a time point when GSIS is impaired), cellular ATP content did not increase with high glucose exposure ([Figure 3](#fig3){ref-type="fig"}A). Application of genipin had no impact on cellular ATP content at ZT 4, suggesting no available target for genipin at this time point (i.e. endogenously low UCP2 activity), but reversed the impairment observed at ZT 16 ([Figure 3](#fig3){ref-type="fig"}A). Similar results were seen in islets isolated from C57BL6 mice at ZT 4 (light/inactive phase) and ZT 16 (dark/active phase) ([Figure 3](#fig3){ref-type="fig"}B). Collectively, these findings demonstrate that UCP2 controls the capacity of ATP production in a temporal manner, which is an important regulatory signal for GSIS.Figure 3Daily rhythms of UCP2 activity control the temporal capacity of glucose-induced ATP content in MIN6 cells and isolated islets. **(A)** Measurement of ATP content in MIN6 cells after exposure to low (2.8 mM) and high (16.7 mM) glucose concentrations. Glucose-induced ATP content was impaired at ZT 16 compared to ZT 4. Application of genipin (50 μM, 1 h before assay) prevented the impairment of glucose-induced ATP content at ZT 16. N = 6--12 independent experiments. **(B)** Measurement of ATP content in islets isolated from WT C57BL6 mice at ZT 4 (10am) and ZT 16 (10 pm). Application with genipin (50 μM, 1 h before assay) prevented ATP content suppression at ZT 4 but had no impact at ZT 16. n = 12--18 mice per time point. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.Figure 3

3.3. Dynamic *Ucp2* expression is required for normal cycles of glucose tolerance over 24 h {#sec3.3}
-------------------------------------------------------------------------------------------

It is well-known that glucose tolerance fluctuates over a 24-hour period such that mild glucose intolerance occurs in the fasting/inactive phase of the daily cycle [@bib37], [@bib38], [@bib39], [@bib40] and our results so far suggest that UCP2 plays an important role in controlling the glucose-stimulated insulin secretion response. To determine if dynamic *Ucp2* expression contributes to the overall pattern of glucose tolerance over a 24 h cycle, we performed i.p. glucose tolerance tests (GTTs) every 4 h over 24 h in *Ucp2-*βKO and *Ins2*-cre control mice. Note that mice were given *ad libitum* access to food, but were fasted 3 h prior to the GTT to ensure baseline blood glucose levels at the start of the test. *Ins2*-cre control ([Figure 4](#fig4){ref-type="fig"}A -- light panels; [Figure 4](#fig4){ref-type="fig"}B) and C57BL6 mice (not shown) both displayed normal rhythms of glucose tolerance, which include improved glucose tolerance in the dark/active phase and mild glucose intolerance in the fasted/inactive phase. Interestingly, *Ins2*-cre control and *Ucp2-*βKO mice displayed no difference in glucose tolerance in the dark/active phase of the daily cycle ([Figure 4](#fig4){ref-type="fig"}A -- dark panels; [Figure 4](#fig4){ref-type="fig"}B); however, *Ucp2-*βKO mice displayed greater glucose intolerance in the light/inactive phase ([Figure 4](#fig4){ref-type="fig"}A -- light panels; [Figure 4](#fig4){ref-type="fig"}B). Rhythmic *Ucp2* expression, particularly the upregulation of *Ucp2* expression in the light/inactive phase, appears to be required for the regulation of normal cycles of glucose tolerance over a 24 h period.Figure 4UCP2 deficiency impairs glucose tolerance only in the light phase of the daily cycle. **(A)** Assessment of glucose tolerance by i.p. GTT test was performed at 4 h intervals over 24 h at the following times: i) ZT0 (6 am -- lights on), ii) ZT4 (10 am), iii) ZT 8 (2 pm), iv) ZT12 (6 pm -- lights off), v) ZT16 (10 pm), and vi) ZT20 (2 am). Open squares are *Ins2*-cre mice; Closed squares are *UCP2-*βKO mice. **(B)** AUC calculations of each glucose tolerance curve in A. N = 18--25 mice per group. \*p \< 0.05; \*\*p \< 0.01.Figure 4

4. Discussion {#sec4}
=============

Glucose tolerance in healthy human subjects is greatest in the morning, just before the onset of the feeding phase, whereas glucose tolerance declines significantly in the evening/night, at the onset of the fasted phase [@bib37], [@bib38], [@bib39], [@bib40]. While daily fluctuations in peripheral insulin sensitivity likely contribute to this phenomenon, the "*capacity*" of GSIS varies over 24 h and contributes significantly to diurnal variations in glucose tolerance [@bib41], [@bib42], [@bib43], [@bib44]. These daily rhythms of GSIS are highly robust and persist in islets isolated from rodent models [@bib43], [@bib44], suggesting that an endogenous diurnal metabolic regulator in islets controls the temporal capacity of GSIS and ultimately glucose tolerance; however, the intrinsic metabolic regulators that control daily fluctuations in GSIS capacity and glucose tolerance have not yet been identified. Here, we have demonstrated in synchronized MIN6 cells and isolated islets that *Ucp2* mRNA displays a rhythmic and predictable expression pattern required for the temporal control of GSIS capacity and glucose tolerance over 24 h, suggesting that *Ucp2* is an important component of the intrinsic metabolic regulator that controls daily fluctuations of GSIS. We also show that fluctuations in GSIS capacity are associated with UCP2-mediated fluctuations in ATP production, which helps to shed some light on current debatable findings in the literature regarding the role of UCP2 in regulating ATP in the β cell. Some studies have demonstrated that *Ucp2* knockout augments ATP production [@bib11], [@bib13], while others demonstrate no impact on ATP [@bib14], [@bib36]. Here, we show that the impact of UCP2 on glucose-induced ATP production is dynamic over a 24 h time course, suggesting that previous discrepancies in the literature may relate to time of day differences when performing actual assessments.

While this study demonstrates that *Ucp2* expression is dynamic in β cells, it is not clear what drives this rhythmic expression. Recent studies have demonstrated that pancreatic islets have remarkably robust endogenous circadian oscillators [@bib35], [@bib45], [@bib46], [@bib47]. Cell-autonomous expression of CLOCK/BMAL1 (core transcriptional activator of the circadian machinery) drives 24 h rhythms of GSIS in isolated wild type islets [@bib48]. Interestingly, it has been established that ∼27% of the β cell transcriptome displays circadian oscillations [@bib48] and that a number of biological pathways involved in the regulation of insulin secretion and oxidative phosphorylation display enriched expression profiles in the dark/active phase of the daily cycle [@bib49]. Additionally, the *Ucp2* promoter contains tandem double E-box elements [@bib50], which are known binding sites for the CLOCK/BMAL1 complex [@bib48]; however, chromatin immuno-precipitation (ChIP) of INS1 832/13 cells with anti-BMAL1 antibody and qPCR with primers flanking the putative BMAL1-binding E-Box elements did not show enrichment of *Ucp2* [@bib46], suggesting that *Ucp2* may not be a direct transcriptional target of BMAL1. Notably, these studies were performed in an unsynchronized clonal β cell line and temporal analyses in primary β cells may yield different results, preventing the exclusion of this possibility. While circadian clock-controlled expression of *Ucp2* is an attractive possibility, it is also possible that temporal *Ucp2* expression is dictated by daily fluctuations in fasting/feeding rhythms and nutrient availability. Exposure to elevated free fatty acids has been shown to induce upregulation and activation of UCP2 in β cells [@bib13], [@bib20], [@bib50], [@bib51], and circulating levels of free fatty acids are significantly increased during fasting. Clearly, further studies are needed to determine what drives the daily cycles of *Ucp2* expression in the pancreatic β cell, but nutritional and circadian cycles are a logical place to start.

At the outset of this study, we hypothesized that rhythmic expression of *Ucp2* would not only regulate daily cycles of insulin secretion but also daily cycles of glucose tolerance. In a 2011 study [@bib14], we assessed glucose tolerance in *Ins2*-cre and *Ucp2-*βKO mice at a single time point (which corresponded with ZT 4 in the current study) and showed impaired glucose tolerance in *Ucp2-*βKO mice despite them having significantly elevated GSIS capacity. In this earlier study, we further demonstrated that excessive glucagon secretion in *Ucp2-*βKO mice, which resulted from aberrant intra-islet reactive oxygen species signaling originating from *Ucp2*-deficient β cells, was an important contributing factor to glucose intolerance development in these mice. In the current study, we have demonstrated a similar phenomenon where *Ucp2-*βKO mice displayed impaired glucose tolerance despite experiencing augmented GSIS capacity, but *only in the light phase* on the daily cycle. No difference in glucose tolerance was observed in *Ucp2-*βKO and *Ins2*-cre in the dark/active phase, a phase when both groups of mice displayed similar GSIS capacities and have low (or no) *Ucp2* expression. These findings suggest that β cell *Ucp2* deletion does not chronically impair glucose tolerance but rather selectively contributes to the control of glucose tolerance in the light/inactive phase as the animal enters into an acute period of fasting. Based on our previous studies on the *Ucp2-*βKO mouse, it would appear that β cell *Ucp2*-mediated regulation of glucagon secretion is an important contributor to the control of glucose tolerance and in the light/inactive phase; however, it is not currently clear how rhythmic expression of *Ucp2* in the β cell affects the 24 h function of the α cell. Further experimentation, which is beyond the scope of this current study, is required to delineate this β cell *Ucp2*-α cell axis in the regulation of 24 h glucose tolerance.

In terms of limitations of this study, we acknowledge that our *Ucp2-*βKO mouse was created using the *Ins2* promoter to drive cre recombinase expression. Unfortunately, it has been demonstrated that *Ins2* is also expressed in glucose-sensing regions of the brain [@bib52], and we have previously demonstrated minor *Ucp2* deletion occurs in the hypothalamus of the *Ucp2-*βKO mouse [@bib14]. Although the identity, function, and contribution of the *Ins2*-expressing neurons to glucose-sensing in the hypothalamus remains unknown, we cannot rule out that *Ucp2* deletion in the brain may contribute to the results of this study, particularly the assessment of whole body glucose tolerance. Notably, we were able to demonstrate that daily rhythms of *Ucp2* expression contribute to daily cycles of GSIS capacity both in islets *ex vivo* as well as in clonal cell lines; models that are removed from central nervous system influence. The use of an *Ins1* cre model for β cell-specific *Ucp2* deletion (as *Ins1* is not expressed in the brain [@bib53]) is suggested to validate the glucose tolerance findings in this paper.

5. Conclusions {#sec5}
==============

For almost two decades, islet biologists have been in pursuit of the physiological function of UCP2 in pancreatic β cells and many suggested functions have been hypothesized. Here, we explored the endogenous patterns of *Ucp2* expression in both isolated islets and mouse clonal MIN6 cells and demonstrated that *Ucp2* mRNA is not only dynamically and rhythmically expressed, but also that this rhythmic expression is required for the temporal control of glucose-stimulated ATP production, normal rhythms of GSIS capacity, and, ultimately, normal rhythms of glucose tolerance. From this, we conclude that UCP2 is part of an important, endogenous, diurnal metabolic regulator that coordinates islet function with anticipated changes and cycling of nutrient availability to regulate temporal glucose tolerance. Given its negative impact on GSIS and its associated upregulation in obesity and diabetes, several groups have suggested that *Ucp2*/UCP2 would make an attractive target for the creation of novel T2D therapies; however, given this novel physiological function of UCP2, targeting *Ucp2*/UCP2 as a therapy for T2D or other metabolic diseases must take into account the rhythmic nature of its expression and its impact on glucose tolerance over 24 h, specifically during the fasted phase.
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